Nurix Therapeutics annual stock-based compensation
2019
2020
2021
2022
2023
2024
2025
Nurix Therapeutics Stock-Based Compensation Growth & History (NRIX)
Nurix Therapeutics's stock-based compensation was $38.0M for fiscal 2025.
View full Nurix Therapeutics company overviewNurix Therapeutics annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-11-30 | $38.0M | $4.0M | +11.90% |
| 2024 | 2024-11-30 | $33.9M | $256,000 | +0.76% |
| 2023 | 2023-11-30 | $33.7M | $5.5M | +19.70% |
| 2022 | 2022-11-30 | $28.1M | $12.3M | +78.04% |
| 2021 | 2021-11-30 | $15.8M | $11.5M | +267.36% |
| 2020 | 2020-11-30 | $4.3M | $3.8M | +743.33% |
| 2019 | 2019-11-30 | $510,000 | — | — |
Nurix Therapeutics quarterly stock-based compensation
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-05-31 | $11.4M | $1.0M | +9.66% |
| Q1 2026 | 2026-02-28 | $9.4M | $682,000 | +7.82% |
| Q4 2025 | 2025-11-30 | $9.1M | $578,000 | +6.79% |
| Q3 2025 | 2025-08-31 | $9.8M | $1.0M | +11.63% |
| Q2 2025 | 2025-05-31 | $10.4M | $1.5M | +17.41% |
| Q1 2025 | 2025-02-28 | $8.7M | $900,000 | +11.51% |
| Q4 2024 | 2024-11-30 | $8.5M | $484,000 | +6.03% |
| Q3 2024 | 2024-08-31 | $8.8M | $309,000 | +3.66% |
| Q2 2024 | 2024-05-31 | $8.8M | $122,000 | +1.40% |
| Q1 2024 | 2024-02-29 | $7.8M | −$659,000 | −7.77% |
| Q4 2023 | 2023-11-30 | $8.0M | −$273,000 | −3.29% |
| Q3 2023 | 2023-08-31 | $8.4M | $1.5M | +20.85% |
| Q2 2023 | 2023-05-31 | $8.7M | $1.9M | +28.75% |
| Q1 2023 | 2023-02-28 | $8.5M | $2.4M | +39.70% |
| Q4 2022 | 2022-11-30 | $8.3M | $3.5M | +71.32% |
| Q3 2022 | 2022-08-31 | $7.0M | $2.7M | +62.02% |
| Q2 2022 | 2022-05-31 | $6.8M | $2.8M | +71.78% |
| Q1 2022 | 2022-02-28 | $6.1M | $3.4M | +124.85% |
| Q4 2021 | 2021-11-30 | $4.8M | $2.3M | +90.97% |
| Q3 2021 | 2021-08-31 | $4.3M | $3.2M | +286.82% |
| Q2 2021 | 2021-05-31 | $3.9M | $3.5M | +732.07% |
| Q1 2021 | 2021-02-28 | $2.7M | $2.5M | +1434.09% |
| Q4 2020 | 2020-11-30 | $2.5M | — | — |
| Q3 2020 | 2020-08-31 | $1.1M | — | — |
| Q2 2020 | 2020-05-31 | $474,000 | — | — |
| Q1 2020 | 2020-02-29 | $176,000 | — | — |
Nurix Therapeutics stock-based compensation trends
Over the last five fiscal years, Nurix Therapeutics's stock-based compensation increased from $4.3M to $38.0M, a change of $33.7M. The latest reported quarter, Q2 2026, shows $11.4M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Nurix Therapeutics source filings ↗